Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 7/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.59 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.59 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.59 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.59 |
| ▸ | TTR | P02766 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9605427 | 0.87 | CYP1A1 (0.69) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| SCHEMBL9605424 | 0.84 | LCK (0.55) | PTGS1PTGS2APPHDAC6ABL1 | |
| SCHEMBL13630652 | 0.81 | PTGS1 (0.65) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| SCHEMBL28524463 | 0.78 | PTGS1 (0.71) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| Resveratrol SCHEMBL27998695 | 0.78 | PTGS1 (0.95) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| SCHEMBL9060269 | 0.77 | NFE2L2 (0.62) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| SCHEMBL20929819 | 0.76 | PTGS1 (0.57) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| Resveratrol SCHEMBL19426 | 0.75 | PTGS1 (1.00) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| Resveratrol SCHEMBL20164915 | 0.75 | PTGS1 (1.00) | PTGS1PTGS2KDM4ELMNACYP1A1 | |
| Resveratrol SCHEMBL19425 | 0.75 | PTGS1 (1.00) | PTGS1PTGS2KDM4ELMNACYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | US ARMY, SECRETARY OF THE ARMY | 2012-05-31 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | PTGS1 3012/4885PTGS2 2856/4885KDM4E 1406/4885 |
| US-20120135091-A1 | METHODS AND COMPOSITIONS FOR ENHANCING LIFESPAN INVOLVING SIRTUIN-MODULATING COMPOUNDS AND CHALCOGENIDES | HSF1, SIRT1, SIRT2 | PTGS1 168/4885PTGS2 192/4885KDM4E 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.